Cabergoline
Cabergoline is a tablet taken once or twice a week that shrinks prolactin-secreting pituitary tumours and normalises hormone levels in most patients, so surgery is reserved for the few whose tumours resist or who cannot tolerate it.
Overview
Cabergoline is an ergoline dopamine agonist developed by Farmitalia Carlo Erba, later Pharmacia and now Pfizer. The FDA approved it in 1996 for hyperprolactinaemic disorders. Its long half-life allows dosing once or twice weekly, and it normalises prolactin in roughly 80 to 90 percent of patients and shrinks macroprolactinomas in most, with less nausea than bromocriptine.
It is the first-line treatment for prolactinoma of any size; transsphenoidal surgery is reserved for resistance, intolerance or cystic tumours compressing the optic chiasm. High doses used in Parkinson's disease were linked to cardiac valve fibrosis, so echocardiographic monitoring is advised on long-term higher doses. The pituitary tumours page names it as the standard treatment for prolactinomas.
A potent, long-acting dopamine D2 agonist that suppresses prolactin release from pituitary lactotrophs and shrinks prolactinomas, taken only once or twice a week. Connects to Dopamine D2 receptor.
1.Cabergoline slips into a pocket on Dopamine D2 receptor.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 1996 | Hyperprolactinaemic disorders, idiopathic or due to pituitary adenomas |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Cabergoline" OR ABSTRACT:"Cabergoline" OR TITLE:"Dostinex" OR ABSTRACT:"Dostinex" OR TITLE:"Cabaser" OR ABSTRACT:"Cabaser") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cabergoline, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentPegvisomant
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Pfizer (incl. Seagen) and the tag subtype-drugs-wave.
- TreatmentMetyrapone
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag subtype-drugs-wave.
- TreatmentOsilodrostat
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag subtype-drugs-wave.
- TreatmentPasireotide
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag subtype-drugs-wave.
- TreatmentCelecoxib
Shares Pfizer (incl. Seagen) and the tag subtype-drugs-wave.